Generation of transgenic human soluble amyloid precursor protein alpha expressing mice
US8008539B1 · kind B1 · utility
3Cited by
7References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 19, 2010 |
| Grant date | Aug 30, 2011 |
| Priority date | — |
| Expiry date | Mar 19, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/0318
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to a novel animal model for neurological degenerative diseases, especially autism, relating to overexpression of human secreted APP-alpha. This novel animal model exhibits several aspects of amyloidopathy. The present invention also relates to a method for producing the double transgenic animals, to cells and cell lines derived from these animals. Moreover, a method for the evaluation of the in vivo effects of a test compound on secreted APP-alpha expression and autism pathology in these animals is provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.